The synergy between cannabidiol and probiotics curtails the glycemic indicators, enhances insulin production, and alleviates the symptoms of type 2 diabetes.

Abstract

Diabetes continues to challenge healthcare system as one of the most growing epidemics with staggering economic burden. It is estimated that 783 million by 2045 will live with diabetes worldwide, 90% of those cases are type 2 diabetes (T2D). T2D is a multifaceted disease, its treatment requires a holistic approach, beyond single target medications with high efficacy. There is a dire need to explore and invent new and effective therapeutic modalities for T2D. In this study we tested whether a combined formulation of cannabidiol (CBD) and probiotics could control glycemic indices and alleviate symptoms of T2D. We used a mouse model of T2D, replaced their drinking water with a combination of CBD and probiotics formulated as a commercially available beverage. Our findings demonstrated that combination of CBD and probiotics not only reduced the glycemic indices (HbA1c & FBG), but also altered the microbiome profile, promoted beneficial bacteria. Further, the CBD/probiotic combination reduced peripheral inflammatory cytokines and enhanced insulin production in pancreatic islets. In conclusion, our results suggest that consumption of combined CBD and probiotics could be used as a natural, practical, affordable, and safe alternative and complementary therapeutic modality to treat T2D.